PhotoCure ASA (LTS:0IMT) Stock Based Compensation: kr17.5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IMT PhotoCure ASA LTS:0IMT
66 GF Score
Price kr54.40
GF Value kr80.28
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA Stock Based Compensation?

PhotoCure ASA LTS:0IMT +2.45% 66 Stock Based Compensation is kr17.5 Mil as of Jun. 2026. GuruFocus rates LTS:0IMT with a GF Score™ of 66/100 and a GF Value™ of kr80.28 (Significantly Undervalued). The stock has 1 warning sign investors should review.

PhotoCure ASA's Stock Based Compensation for the three months ended in Jun. 2026 was kr3.6 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was kr17.5 Mil.

PhotoCure ASA Stock Based Compensation Related Terms

PhotoCure ASA Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for PhotoCure ASA's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhotoCure ASA Stock Based Compensation Chart

PhotoCure ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.67 22.18 20.16 16.97 18.79

PhotoCure ASA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.38 4.82 4.76 4.33 3.60
LTS:0IMT
66GF Score
PhotoCure ASA LTS:0IMT
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhotoCure ASA Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr17.5 Mil.

What does a Stock Based Compensation of kr17.5 Mil mean?
PhotoCure ASA (LTS:0IMT) has a Stock Based Compensation of kr17.5 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PhotoCure ASA and its competitors.
Is PhotoCure ASA's Stock Based Compensation too high?
PhotoCure ASA's current Stock Based Compensation is kr17.5 Mil. Overall, PhotoCure ASA has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Stock Based Compensation compare to ZTS and UTHR?
PhotoCure ASA's Stock Based Compensation of kr17.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PhotoCure ASA and its competitors. PhotoCure ASA's current Stock Based Compensation is kr17.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (LTS:0IMT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr80.28, compared to a current price of kr54.40 — trading 32.2% below its estimated fair value. The current Stock Based Compensation is kr17.5 Mil. PhotoCure ASA's overall GF Score™ is 66/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For PhotoCure ASA (LTS:0IMT), the current Stock Based Compensation is kr17.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhotoCure ASA (LTS:0IMT) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of kr54.40 is trading 32.2% below its estimated GF Value™ of kr80.28. GuruFocus considers PhotoCure ASA to be Significantly Undervalued.

Key valuation signals for LTS:0IMT:

  • Stock Based Compensation: kr17.5 Mil
  • GF Value™: kr80.28 vs. price of kr54.40 (32.2% below fair value)
  • GF Score™: 66/100 with 1 warning sign

No single metric tells the full story. See the LTS:0IMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
66GF Score

Get the complete analysis for LTS:0IMT

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr54.40
Price
kr80.28
GF Value